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classification system in patients with somatic
conditions: validity and performance
Katerina Papageorgiou1*, Karin M Vermeulen2, Maya J Schroevers1, Erik Buskens2 and Adelita V Ranchor1Abstract
Background: Valuations of depression are useful to evaluate depression interventions offered to patients with
chronic somatic conditions. The only classification system to describe depression developed specifically for
valuation purposes is the McSad, but it has not been used among somatic patients. The aim of this study was to
test the construct validity of the McSad among diabetes and cancer patients and then to compare the McSad to
the commonly used EuroQol – 5 Dimensions (EQ-5DTM) classification system. The comparison was expected to
shed light on their capacity to reflect the range of depression states experienced by somatic patients.
Methods: Cross-sectional data were collected online from 114 diabetes and 195 cancer patients; additionally, 241
cancer patients completed part of the survey on paper. Correlational analyses were performed to test the construct
validity. Specifically, we hypothesized high correlations of the McSad domains with depression (Center for
Epidemiological Studies Depression Scale (CES-D) and the Patient Health Questionnaire (PHQ-9)). We also expected
low/moderate correlations with self-esteem (Rosenberg Self-Esteem scale - RSE) and extraversion (Eysenck
Personality Questionnaire Extraversion scale - EPQ-e). Multiple linear regression analyses were run so that the
proportion of variance in depression scores (CES-D, PHQ-9) explained by the McSad could be compared to the
proportion explained by the EQ-5D classification system.
Results: As expected, among all patients groups, we found moderate to high correlations for the McSad domains
with the CES-D (.41 to .70) and the PHQ-9 (.52 to .76); we also found low to moderate correlations with the RSE
(-.21 to .-48) and the EPQ-e (.18 to .31). Linear regression analyses showed that the McSad explained a greater
proportion of variance in depression (CES-D, PHQ-9) (Diabetes: 73%, 82%; Cancer: 72%, 72%) than the EQ-5D
classification system (Diabetes: 47%, 59%; Cancer: 51%, 47%).
Conclusions: Findings support the construct validity of the McSad among patients with somatic conditions and
demonstrate that it performs better than the EQ-5D classification system to reflect the range of depression states.
For future valuation purposes, the McSad classification system could therefore be recommended to describe
depression as experienced by patients with a chronic medical condition.Background
Depression is more prominent among patients with
chronic medical conditions than in the general population
[1,2]. Diabetes [3,4], cancer [5,6], heart disease [7], chronic
obstructive pulmonary disease [8], and renal disease [9]
are among the somatic conditions for which elevated rates
of depression have been reported. Depressive symptoms* Correspondence: a.papageorgiou@umcg.nl
1Health Psychology Section, University of Groningen, University Medical
Center Groningen, Groningen, The Netherlands
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distribution, and reproduction in any mediumrepresent a major burden for those patients, reducing their
Health Related Quality of Life (HRQoL) and hampering
their daily functioning [10-12]. It is important to assess de-
pression specific HRQoL when evaluating the effectiveness
of depression interventions offered to patients with som-
atic conditions.
Health state valuations (also called “utility values”, “util-
ities”, or “preferences”) are used to numerically express
the HRQoL associated with a health state. Values repre-
sent “preferences” for specific health states and range from
0 (usually “worst imaginable health”) to 1 (usually “bestentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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applicable to different types of health conditions. These
valuations are therefore convenient as HRQoL outcome
measures for the economic evaluations of health care in-
terventions [13]. Valuation occurs in two steps; first the
health state is described/identified, and then it is valued.
An appropriate and valid description of the state is a pre-
requisite for a valid valuation.
Generic utility measures such as the EQ-5D [14] and
the SF-6D [15] are commonly used for the description
and valuation of health states. The descriptive formats
are often accompanied by scoring algorithms to assign
indirect values to those states. As the classification sys-
tems are based on generic HRQoL domains, they are
suitable for a wide range of somatic conditions. Al-
though generic utility measures have also been used for
valuations of depression [14,16-23], their suitability for
mental health states has been questioned. The literature
suggests a limited sensitivity of generic utility measures
to capture changes in depression [24,25], but the evi-
dence is neither consistent nor sufficient to draw definite
conclusions [26,27].
The McSad is the only classification system developed
specifically to generate descriptions of depression states
for valuation purposes [28]. Similarly to generic systems
such as the EQ-5D, the McSad is a brief self-report meas-
ure that puts a low burden on the respondent, thereby giv-
ing it high feasibility for large samples of respondents. The
McSad consists of six depression domains defined on the
basis of DSM III, each comprising four levels of function-
ing. It can therefore generate a large number of profiles
for depression and reveal subtle differences among them.
Its content validity was determined by reviewing experts’
evaluations. Its construct validity was demonstrated by
consistent relationships between the severity of depression
and the valuations provided by a population of outpatients
with remission in their depression. The values for depres-
sion states generated by the McSad [28] have been used as
outcome indices in a number of economic studies of de-
pression interventions [29-34].
The McSad also seems suitable for patients with chronic
medical conditions, though it has not been used before in
this population. Its suitability thus needs to be demon-
strated, starting with its classification system. It should be
tested prior to and independent of its application for valu-
ation purposes [35]. Specifically, the McSad may be
deemed appropriate to describe depression among pa-
tients with somatic conditions for valuation purposes
when it meets two conditions: first, it must have validity;
second, it must perform better than commonly used gen-
eric measures.
This cross-sectional study examines the properties of
the Dutch version of the McSad classification system to
reflect depression among patients with chronic somaticconditions. Our first aim was to test the construct validity
(convergent and divergent) by formulating and testing hy-
potheses regarding relationships of the McSad with se-
lected measures. Our second aim was to test the capacity
of the McSad to reflect the range of depression states,
compared to the EQ-5D classification system (CS).
Method
Participants and data collection
The following inclusion criteria were used: aged 18 to 80
years; self-reported diagnosis of diabetes (Type I or II) or
cancer (any type); and signed informed consent. For the
sake of generalization, we included two separate etiology
groups: diabetes and cancer. While both conditions carry
a high risk for depressive symptomatology, they differ con-
siderably. For example, cancer is directly related to the risk
of death, and its treatment is often intensive, e.g. surgery
or chemotherapy [36]. Diabetes, on the other hand, is not
directly related to risk of death, and its primary treatment
mostly involves management of glucose levels [37].
An online survey was carried out from September 2010
through November 2011 using the Unipark software pack-
age (www.unipark.com). Diabetes patients were recruited
through the www.dvn.nl site (Diabetes Association
Netherlands). Cancer patients were recruited through the
following sites: www.nfk.nl (Dutch Federation of Cancer
Patient Organizations); www.borstkankertrefpunt.hyves.nl
(forum for people dealing with breast cancer issues); www.
olijf.nl (network for women with gynecological cancer).
The patient associations behind these sites were contacted
to inform them about the study and request them to host
the survey. Once permission was granted, the web page
posted a link to the survey, stating the affiliation and the
general purpose of the study. Anyone who visited the site
could see the posting; those choosing to follow the link
could read more about the purpose of the study and eligi-
bility to participate in it. Those who signed the informed
consent could go on to complete the survey.
For the sake of simplicity, we refer to the online par-
ticipants as the Diabetes and the Cancer groups. An
additional group of cancer patients completed a brief
version of the survey on paper. We refer to the latter
participants as the Cancer-paper group. The reason to
have an additional group was to cross-check some of
our findings in patients that differed in terms of admin-
istration (paper vs. computer) and recruitment method
(physician instead of internet). Members of the Cancer-
paper group were approached by their physicians at the
Radiotherapy Department of the University Medical
Center Groningen during the period April to November
2011. They were contacted in the context of an ongoing
project of the Health Psychology Section, University
Medical Center Groningen. Patients giving their in-
formed consent were sent a paper survey by post.
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provided information on their gender, age, years since
diagnosis, and the existence of other important medical
conditions. Next, the McSad classification system was
presented as a self-report health check list. The respon-
dents were asked to identify their level of functioning
within the previous week. Finally, they completed de-
pression questionnaires and provided information for
other scales. Participants in the Cancer-paper group first
answered the personal and disease-related questions and
then provided the other information, though only on the
McSad and a depression scale.
McSad classification system
The McSad was designed to describe Major Unipolar De-
pression for valuation purposes. It distinguishes six do-
mains of distinct depressive symptoms, in accordance
with the DSM-III [38]. Each one (Emotion, Self-appraisal,
Cognition, Physiology, Behavior, and Role function) recog-
nizes four levels of dysfunctioning: no (1), mild (2), moder-
ate (3), and severe (4). The Emotion domain combines
symptoms of a blue mood and a loss of interest (example
of mild dysfunctioning: “Feel more down (or sad, blue, de-
pressed) than usual and don’t enjoy things as usual”). The
Self-appraisal domain concerns how one views the self
and the world (example of mild dysfunctioning: “Don’t feel
very good about myself these days and often see the down-
side of everything”). The Cognition domain describes cog-
nitive performance such as concentration, memory, and
decision-making (example of mild dysfunctioning: “Have
some trouble concentrating and remembering these days,
and it seems harder to make decisions”). The Physiology
domain refers to physical symptoms of depression such
as sleep, energy, and appetite (example of mild dys-
functioning: “Sleep is quite troublesome these days. Don’t
have quite the normal get up and go, and have less of an
appetite”). The Behavior domain relates to symptoms of
psychomotor agitation/retardation and, in the more severe
categories, to suicidal ideation (example of mild dys-
functioning: “Things are more of a chore these days and at
times I feel sluggish or agitated”). Finally, the Role function
domain addresses performance in work, home, or social
settings (example of mild dysfunctioning: “Able to function
okay at work, home, school, or with friends but often don’t
enjoy what I am doing, and/or feel more withdrawn
lately”). The full version of this classification system is
available in the publication by Bennett et al. [28]. McSad is
a self-report instrument. For each of the six domains, re-
spondents are asked to choose the one level that best de-
scribes how they had functioned during the past week. The
answers generate a single metric representing a descriptive
profile (for example, profile 232322 describes mild dys-
functioning in Emotion, Cognition, Behavior, and Role
function and moderate dysfunctioning in Self-appraisal andPhysiology). All possible combinations of the four levels in
the six domains would generate 4096 (46) unique descrip-
tive profiles of depression states.
For the purposes of the current study, the McSad was
translated into Dutch, using established forward-backward
translation guidelines [39,40], i.e., translated into Dutch
and then back to English. The Dutch translation was made
by a group of researchers at the Health Psychology Section
of the University Medical Center Groningen (one profes-
sor, two senior researchers, and one research assistant), all
of whom are native Dutch speakers and fluent in English,
with extensive experience in using depression scales for
research among patients with somatic conditions. Then an
expert in English with no prior knowledge of the question-
naire was engaged for the back translation. The translated
versions were discussed in order to reach consensus on
slight differences in wording. Content validity was assessed
by the same group; they assessed whether all depression
symptoms are covered by the McSad and how consistently
the four levels reflect the levels of dysfunctioning in each
domain. Given that the McSad was developed on the basis
of DSM criteria, we first made a point-by-point compari-
son of the DSM and the McSad. Furthermore, we com-
pared the McSad with depression scales commonly used
among patients with somatic conditions (PHQ-9, CES-D,
and HADS). After assessing the content validity, minor
changes were made in levels 3 and 4 of the Behavior do-
main with regard to suicidal tendency, as the way they had
been formulated was considered extremely negative.
In order to test the McSad psychometrically, each do-
main was assigned a score from 1 (no dysfunctioning) to
4 (severe dysfunctioning).
Construct validity
To test construct validity of the McSad, we examined the
correlations of the McSad domains (i.e. domain scores)
with depression scales (i.e. total scores), as well as with
other scales measuring constructs related to depression,
that is self-esteem and extraversion. In light of our con-
ceptual framework, based on theory and previous re-
search, we formulated working hypotheses regarding the
construct validity of the McSad. Specifically, we hypothe-
sized higher correlations of the McSad domains with the
depression scales (convergent validity) than with self-
esteem and extraversion scales (divergent validity).
Convergent validity
Hypotheses
We hypothesized that the aggregate scores for the Cancer
and Diabetes groups on all McSad domains would correl-
ate strongly with their total scores on the two depression
scales investigated here, i.e., the Center for Epidemio-
logical Studies Depression Scale (CES-D) [41,42] and the
Patient Health Questionnaire (PHQ-9) [43]. We also
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and the CES-D for the Cancer-paper group. As differences
in the administration and recruitment method were not
expected to exert any influence on the hypothesized rela-
tionships of the McSad with the depression scales, we
expected to find strong correlations in this group too.
Measures
The Patient Health Questionnaire (PHQ-9) is a depression
scale consisting of nine items. These correspond to DSM
depression criteria such as blue mood and sleep problems.
Items are presented as questions about the frequency of
depression symptoms within the past two weeks. Answer
categories range from 0 (“not at all”) to 3 (“almost every
day”). The item scores are summed to calculate the total
depression score, which ranges from 0 (no symptoms) to
27 (highest level of depression). The PHQ-9 has been
demonstrated to be a reliable and valid instrument for
screening for depression and for assessing its severity, also
among populations with a background of medical issues.
A mean score of 5.08 on the PHQ-9 questionnaire has
been reported for primary care patients [44]. The previ-
ously validated Dutch version of the PHQ-9 was used here
[45]. In the current samples, internal consistency was
good, as indicated by high Chronbach’s alphas of .90 and
.83 in the Diabetes and Cancer groups, respectively.
The Center for Epidemiological Studies Depression
Scale (CES-D) is a validated self-report scale for assessing
depressive symptoms. It consists of 20 items representing
symptoms of depression. These concern a depressed
mood, feelings of guilt and worthlessness, feelings of help-
lessness, psychomotor retardation, loss of appetite, and
sleep disturbance. The scale addresses the frequency of
such symptoms within the last week. Items are scored on
a four-point scale ranging from 0 (rarely or none of the
time, i.e., <1 day) to 3 (most or all of the time, i.e., 5-7
days). Four of the items are phrased in reverse order and
recoded accordingly. Item scores are summed to calculate
the scale score, which ranges from 0 to 60, with higher
scores representing higher levels of depression. The CES-
D has also been validated among patients with chronic
medical conditions [46,47]. An average CES-D score of
about 12 has been reported for cancer patients under
treatment [48,49]. The validated Dutch version of the scale
was used here [50]. In the current samples, internal
consistency was good, as indicated by high Chronbach’s al-




In accordance with the literature, we hypothesized that
all six McSad domains would show moderate correla-
tions with self-esteem [51,52] and weak correlations withextraversion [53]. We then examined the correlations of
the McSad domains with Rosenberg’s self-esteem scale
[54] and the Eysenck Personality Questionnaire – Extra-
version scale [55].
Measures
Rosenberg’s Self-Esteem scale (RSE) is used to assess
one’s level of self-esteem. It includes ten items related to
self-esteem as reflected by respondents. For example,
one item states, “I feel that I have a number of good
qualities”. Items are answered on a four-point scale, ran-
ging from 1 (“strongly agree”) to 4 (“strongly disagree”).
Five items (1, 2, 4, 6, 7) are worded positively, the other
five (3, 5, 8, 9, 10) negatively. Negative items are reverse-
coded. A total scale score is calculated by summing the
item scores, thus ranging from 10 to 40, with higher
scores indicating higher self-esteem. The reliability and
validity of this scale have been demonstrated [56].
The Eysenck Personality Questionnaire – Extraversion
scale (EPQ-e) consists of 12 items to assess extraversion.
These are posed as questions; for example, “Are you a
talkative person?” The participants are asked to answer
on a dichotomous scale (yes: 1; no: 0). The total score
for the scale is calculated by summing the item scores;
thus, the total can range from 0 to 12, with higher scores
indicating higher extraversion. The psychometric prop-
erties of the EPQ have been established [57-59].
Comparison of the McSad to the EQ-5D classification
system
Hypothesis
To assess the capacity of the McSad to reflect the range
of depression states experienced by patients with som-
atic conditions, we examined the degree of variability in
depression scores that can be explained by the McSad
and compared that outcome to the degree of variability
in depression scores that can be explained by the EQ-5D
CS [14]. We hypothesized that altogether the six McSad
domains would account for a large proportion of vari-
ability in the depression scores assessed by the CES-D
and the PHQ-9. Further, we expected this proportion to
be larger than that explained by all the EQ-5D domains.
Measures
The EuroQol – 5 Dimensions (EQ-5DTM) is a generic
health status measure. It consists of a classification sys-
tem and a Visual Analogue Scale. The present study
used only its classification system, which comprises five
dimensions: mobility, self-care, daily activities, pain/dis-
comfort, and anxiety/depression. Respondents are asked
to choose the one level out of three (no, moderate, severe
problems) that reflects their current functioning. Their
scores on each domain are combined to generate de-
scriptive profiles appropriate for valuation. In order to
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domain scores ranging from 1 (no problems) to 3 (severe
problems).
Statistical analysis
All the variables were examined for outliers, missing data,
and normality. The Diabetes and Cancer groups were
compared with respect to background variables by means
of t tests and chi-square tests. Similarly, the Cancer-paper
group was compared to the Cancer group.
The McSad was inspected to discern the distribution
of levels and the number of different profiles identified
among the Diabetes and Cancer groups.
Relationships of the McSad domains with the selected
scales were assessed by means of a Spearman’s Rho cor-
relation coefficient, as the assumption of normality of
distribution was violated. Correlations higher than .50
were considered strong, those less than .30 weak [60].
A number of multiple linear regression analyses were
performed to compare the McSad to the EQ-5D CS
concerning their capacity to reflect the range of depres-
sion scores. The first regression analysis examined all six
McSad domains, treating them as predictor variables.
The answer categories were coded as dummy variables
and the Enter method was used, while the total score on
the CES-D was used as an outcome variable. The second
regression analysis was similar to the first except that
the PHQ-9 total score was used as an outcome. The
third and fourth regression analyses were almost equiva-
lent to the first two, though not quite; instead of using
the McSad domains as predictor variables, the EQ-5D
domains were used for that purpose.
All analyses were carried out separately for the Dia-
betes and Cancer groups. Data from the Cancer-paper
group on the McSad and the CES-D were used only to
cross-check convergent validity findings. Statistical sig-
nificance was assumed for p < .05. Data were analyzed
using SPSS, version 16 (SPSS Inc., Chicago IL).
Results
Participants & data description
The sample for the survey consisted of 114 participants
from the Diabetes and 195 from the Cancer group, as well
as 241 from the Cancer-paper group. The profile of the
study with respect to response and completion rates is
presented in Figure 1. The characteristics of the partici-
pants, concerning personal and disease-related informa-
tion as well as levels of depression, are displayed in
Table 1. Women were in the majority in the Diabetes and
Cancer groups (72% and 84% respectively), whereas men
were in the majority (76%) in the Cancer-paper group.
The mean age in all three groups was over 40, and the
number of years since diagnosis varied considerably. Aver-
age levels of depression were found to be lower than thethreshold for clinically relevant symptoms, with the excep-
tion of the Cancer group, but then only when they were
assessed using the CES-D. The Cancer and Diabetes
groups were found to be similar in terms of comorbidity
rates and depression levels. However, participants in the
Diabetes group were more often men, younger, and had
been diagnosed longer ago than participants in the Cancer
group. When compared to the Cancer group, participants
in the Cancer-paper group were more often men, older,
and experienced lower levels of depression.
Items were missing on the McSad for less than 3% of
the cases for all groups, and listwise exclusion was used.
No extreme outliers were identified for the included var-
iables. For most of the variables, the distribution violated
normality, so non-parametric tests were used.
The distribution of levels of severity on the McSad do-
mains for the Diabetes and Cancer groups is displayed
in Figure 2. It clearly shows an overall floor effect in
levels for all six McSad domains and a variation from
normality. Specifically, the percentage of answers falling
into level 3 or 4 ranges from 2% in the Emotion domain
to 18% in the Role function domain for the Diabetes
group. For the Cancer group, answers in these higher
levels range from 4% in the Behavior domain to 24% for
Role function. Of the 114 participants in the Diabetes
group, 77 reported at least mild dysfunctioning on at
least one of the McSad domains. For these 77 respon-
dents, a total of 53 different depression states were iden-
tified by the McSad. Similarly, 163 out of the 195
participants in the Cancer group reported at least mild
dysfunctioning in at least one McSad domain; for these
163 patients, a total of 71 different depression states
were detected.
Construct validity
Table 2 summarizes the results on convergent and diver-
gent correlations of the McSad domains with depression,
self-esteem, and extraversion scales.
Convergent validity
All the correlations between the McSad domains and de-
pression scales were found to be significant. Correlations
were strong for the Diabetes group (CES-D: .50 to .70;
PHQ-9: .65 to .76) and moderate to strong for the Cancer
group (CES-D: .41 to .64; PHQ-9: .52 to .63). Correlations
between the McSad domains and the CES-D were found
to be moderate to strong among the Cancer-paper group
(.43 to .52).
Divergent validity
The correlations between the McSad domains and self-
esteem were found to be statistically significant for both
groups, though moderate in the Diabetes group (-.32
to -.48) and weak in the Cancer group (-.21 to -.29). The
Figure 1 Study profile.
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Physiology domain for the Cancer group. Correlations with
extraversion were found to be significant though weak for
both the Diabetes (.21 to .31) and the Cancer group (.18 to
.30), with the exception of a non-significant correlation in
the Physiology domain for the Diabetes group.
On the whole, all six McSad domains had stronger
correlations with depression scales than with self-esteem
and extraversion.
Comparison of the McSad to the EQ-5D classification
system
The results of the regression analyses are presented at
Additional file 1: Table S1. Due to the very limited num-
ber of participants whose answers fell into the fourth
level on the McSad domains (0 to 18 cases), levels 3 and
4 were merged.
Overall, the results indicate that for both the Diabetes
and the Cancer groups, a substantially larger proportion
of variance in depression scores (CES-D, PHQ-9) could be
explained when the six McSad domains were used as pre-
dictor variables (Diabetes: 73%, 82%; Cancer: 72%, 72%)
than when the EQ-5D domains were used (Diabetes: 47%,
59%; Cancer: 51%, 47%).
Discussion
The McSad depression specific classification system
seems to appropriate for use among patients with som-
atic conditions. However, it has not yet been validated inthis population. Nor has its performance been compared
to that of the commonly used EQ-5D classification sys-
tem. In this study, we examined the McSad among dia-
betes and cancer patients.
Our findings support the expected construct validity
of the McSad. All six McSad domains correlate either
strongly or moderately with depression scales. In con-
trast, the observed moderate/weak associations of
McSad domains with self-esteem and the weak associa-
tions with extraversion are in line with our hypotheses.
Since the McSad demonstrates the types of associations
that would be expected for a depression measure in
light of previous research, we have found evidence in
support of its validity. Furthermore, compared to the
EQ-5D classification system, the performance of the
McSad to reflect the range of depression scores appears
considerably better. Therefore, the McSad seems to be a
valid and appropriate classification system for describ-
ing depression among patients with somatic conditions.
Having found that the McSad, in addition to being
valid, also appeared to perform better than the EQ-5D
classification system in reflecting the range of depression
states, we can recommend applying this instrument in
valuations of depression that can subsequently be used
in cost-utility analyses of psychological interventions for
patients with somatic conditions. Optimally, the McSad
could be used in combination with a generic utility
measure in order to detect depression-specific as well as
general health-related changes.
Table 1 Characteristics of participants
Diabetes Cancer Diabetes vs. vancer Cancer-paper Cancer vs. cancer-paper
N 114 195 241
Age, years
Mean (SD) 44 (14.1) 52 (10.9) t (192) = 5.18** 65.3 (11.6) t (412) = 11.7**
Range 20 - 73 22 - 77 p < .000 36-79 p < .000
Gender
women 82 (72%) 163 (84%) χ2 (1) = 6.36 55 (24.2%) χ2 (1) = 145**
p = .013 p < .000
Years since diagnosis
Median (IR) 13.5 (17) 3 (3) t (128) = 8.52** 3 (3) t (412) = 2.0
Range 0-56 1-31 p < .000 0-25 p = .057
Main co-morbidity
COPD, asthma 9 (7.9%) 19 (9.7%) χ2 (1) = .32 17 (7%) χ2 (1) = 1.08
p = .57 p = .30
Heart 8 (7.0%) 6 (3%) χ2 (1) = 2.52 30 (12.3%) χ2 (1) = 12.32**
p = .11 p = .00
Rheumatoid arthritis 5 (4.4%) 14 (7.2%) χ2 (1) = .46 15 (6.2%) χ2 (1) = 177
p = .50 p = .70
CES-D (depression)
Mean (SD) 14.31 (11.6) 16.09 (9.6) t (190,535) = 1.34 9.9 (7.7) t (352) = 7.0**
Range 0 – 50 0 – 45 p = .181 0-37 p = .000
PHQ-9 (depression)
Mean (SD) 6.41 (6.03) 6.43 (4.69) t (187,889) = .071 -
Range 0 – 25 0 – 27 p = .943
(Columns in italics present results of t and chi-square tests concerning differences among groups).
* p < .05 / ** p < .01.
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its limitations should be considered. Regarding the
sample, the restricted number of participants with
more severe levels of depression and the consequent
floor effect observed in the McSad constrain our ability
to draw conclusions on the capabilities of the McSad
for reflecting more severe levels of depression. Given
that the reported levels of depression were in accord-
ance with what was expected in this population, the
small number of participants with severe depression
could be addressed by increasing the sample size. Fur-
thermore, the relationships between the McSad and the
other scales were examined for each McSad domain. Spe-
cifically, we examined the relationships between domains
(e.g., Cognition) with a whole construct (e.g., Depression),
which could partially explain finding correlations that
were somewhat different than expected. On the other
hand, this approach is appropriate for testing a multi-
attribute classification system that was not designed to
compute a total score. Investigation of two additional is-
sues could further support the conclusions of the currentstudy. First, it can currently not be ruled out that symp-
toms of depression included in the Physiology domain
might overlap with symptoms of the somatic condition
and/or its treatment. For example, apart from being a de-
pression symptom, fatigue is one of the most persistent
side-effects of cancer treatment [61]. Also, sleeping prob-
lems, included in the Physiology domain of the McSad,
are also frequently experienced by patients with diabetes
[62]. Such replication has been previously recognized in
established depression scales such as the PHQ-9, in which
psychometric testing favored inclusion of such symptoms
in the scales. Secondly, a clinical interview, accepted as the
“gold standard” for assessing depression, might be prefera-
ble for testing the validity of the McSad. However, use of
self-report instruments allows us to obtain more informa-
tion on differences in the severity of depression.
One strength of the current study is that the McSad
was tested separately in groups of people with different
somatic conditions, namely diabetes and cancer. An-
other is that it cross-validates some of those questions
in an additional group of patients representing a
Figure 2 Distribution of answer categories (%) on the McSad domains.
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http://www.hqlo.com/content/11/1/125different recruitment and administration method. Our
conclusions are also strengthened by testing and
confirming our hypotheses using two established de-
pression scales (CES-D, PHQ-9).
Further studies on the McSad classification system
among patients with somatic conditions could focus
on its responsiveness, especially before and after an
intervention that is known to meaningfully reduce de-
pression. Comparison of the McSad to the EQ-5D clas-
sification system on their relative capacity to reflect
changes is also warranted. Furthermore, the propertiesTable 2 Construct validity findings
Diabetes
McSad domains CES-D PHQ-9 RSE EPQ-e
Emotion .70** .73** -.43** .24**
Self-appraisal .68** .73** -.48** .26**
Cognition .67** .72** -.45** .21**
Physiology .50** .65** -.32** .16
Behavior .68** .76** -.44** .22**
Role function .68** .74** -.41** .31**
Mean .65 .72 -.42 .23
Correlations (Spearman’s Rho) of McSad domains with depression (CES-D, PHQ-9), s
* p < .05/** p < .01.of the McSad classification system could be studied in
different populations of patients with chronic somatic
conditions associated with increased risk of depres-
sion, for example heart or COPD patients. Finally, the
development of a scoring formula which can be used
to attach values to all the states generated by the
McSad classification system would make the instru-
ment directly available for use in intervention evalua-
tions. This could, in turn, make health valuation more
applicable as an outcome measure in the mental health
field, which is now lagging behind [63].Cancer Cancer-paper
CES-D PHQ-9 RSE EPQ-e CES-D
.64** .52** -.21** .23** .44**
.61** .52** -.25** .30** .45**
.52** .63** -.25** .20** .43**
.41** .62** -.10 .23** .50**
.64** .61** -.29** .22** .52**
.61** .57** -.28** .18* .47**
.57 .58 -.23 .23 .47
elf-esteem (RSE) and extraversion (EPQ-e) scales.
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We examined the McSad depression specific classification
system among patients with somatic conditions. It proved
to be valid and it appears to perform considerably better
than the commonly used EQ-5D classification system.
Given these findings, we conclude that the McSad is the
instrument of choice to reflect depression among patients
with somatic conditions for future valuation studies.
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